Publications in collaboration with researchers from Hospital Universitario de Canarias (18)

2024

  1. SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

    Lupus Science and Medicine, Vol. 11, Núm. 1

  2. Subcutaneous vs intravenous abatacept in rheumatoid arthritis-interstitial lung disease. National multicentre study of 397 patients

    Seminars in Arthritis and Rheumatism, Vol. 68

2022

  1. Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure

    Seminars in Arthritis and Rheumatism, Vol. 52

2021

  1. Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?

    Clinical and Experimental Rheumatology, Vol. 39, Núm. 3, pp. 555-563

  2. Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?

    Rheumatology (Oxford, England), Vol. 60, Núm. 11, pp. 5329-5336

2020

  1. Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality

    Lupus, Vol. 29, Núm. 12, pp. 1556-1565

  2. Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER).

    Seminars in Arthritis and Rheumatism, Vol. 50, Núm. 4, pp. 657-662

  3. Efficacy and Safety of Combined Therapy With Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Systematic Literature Review

    Reumatologia Clinica, Vol. 16, Núm. 5P1, pp. 324-332

  4. Expert Recommendations on the Interleukin 6 Blockade in Patients with Rheumatoid Arthritis

    Reumatologia Clinica, Vol. 16, Núm. 4, pp. 272-281

  5. Hydroxychloroquine is associated with a lower risk of polyautoimmunity: Data from the RELESSER Registry

    Rheumatology (United Kingdom), Vol. 59, Núm. 8, pp. 2043-2051

  6. Prevalence and factors associated with osteoporosis and fragility fractures in patients with primary Sjögren syndrome

    Rheumatology International, Vol. 40, Núm. 8, pp. 1259-1265

  7. Satisfaction, fulfillment of expectations and adherence to subcutaneous biological drugs in patients with rheumatoid arthritis: ARCO study

    Reumatologia Clinica, Vol. 16, Núm. 2P1, pp. 116-119

2018

  1. Biologic Disease-modifying antirheumatic drug attributes in the first lines of treatment of rheumatoid arthritis. 2015 ACORDAR project

    Reumatologia Clinica, Vol. 14, Núm. 2, pp. 90-96

2017

  1. Comorbidities in Patients With Primary Sjögren's Syndrome and Systemic Lupus Erythematosus: A Comparative Registries-Based Study

    Arthritis Care and Research, Vol. 69, Núm. 1, pp. 38-45

  2. Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus

    Seminars in Arthritis and Rheumatism, Vol. 47, Núm. 1, pp. 38-45

  3. Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: A multicentre, non-interventional study

    Clinical and Experimental Rheumatology, Vol. 35, Núm. 3, pp. 423-430

2016

  1. Characterization of patients with lupus nephritis included in a large cohort from the Spanish society of rheumatology registry of patients with systemic lupus erythematosus (RELESSER)

    Medicine (United States), Vol. 95, Núm. 9

  2. Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: Cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry

    Rheumatology (United Kingdom), Vol. 55, Núm. 7, pp. 1243-1250